Breaking News

The female chemist who helped discover GLP-1 — then was erased from the record

September 27, 2023
lev-f-avatar-teal
Addiction Reporter

Good morning! This is Lev Facher, filling in for Liz. As usual, today's newsletter is jam-packed with terrific STAT stories. But I'd be remiss not to single out a true must-read: My colleagues Elaine Chen and Megan Molteni on the pioneering GLP-1 researcher whose research contributions decades ago have been overlooked in favor of three male colleagues.

Health

The female chemist written out of GLP-1 history

FINAL-small-Svetlana-Mojsov-Marian-F.-Moratinos-x-STAT
Marian F. Moratinos for STAT

Svetlana Mojsov has never sought much credit for helping to discover GLP-1, the hormone that's become the basis for blockbuster diabetes and weight-loss drugs like Ozempic and Wegovy. She never thought she had to: The academic paper trail, she believed, spoke for itself. 

But in the decades that followed, as GLP-1 has sparked the development of perhaps the most lucrative drug class in pharmaceutical industry history, Mojsov's name has been all but erased from the record. Meanwhile, three of her male colleagues have won countless awards and citations — and raked in immense royalties from the patents granted in 1992.  

In a new story, STAT's Elaine Chen and Megan Molteni uncover new details about the timing and importance of Mojsov's contributions and her decade-long battle for both recognition and royalties. Read more here


PUBLIC HEALTH

Americans eager for flu shots, more tepid on Covid boosters

Far more Americans intend to be vaccinated against the flu and RSV than against Covid-19, according to a new Kaiser Family Foundation poll: 58% of adults say they'll receive a flu shot, but just 47% say they plan to receive the newest Covid-19 vaccine.

The poll highlights continued resistance to Covid vaccinations among a large share of the U.S. population: Nearly one-quarter of all American adults have never received a Covid-19 vaccination and do not intend to, while another quarter of the population have previously received a coronavirus vaccine but say they won't get the new one. 

Even those who do want the latest vaccines aren't having the easiest time finding one. In a new story, STAT's Helen Branswell writes that a combination of payment and supply issues have made the rollout of the latest jab far more challenging than for previous versions. Read more here


Health

ARPA-H finally gets a home — in fact, it gets thirteen 

The lobbying for the new headquarters of ARPA-H, the Biden administration's new biomedical research agency, stretches back well over a year, even before Congress gave the program any funding. The regions vying to host the government's shiny new science institute — which they viewed as a potential driver of economic growth — included Texas, Ohio, North Carolina, Boston, Philadelphia, and Washington, D.C., to name but a few. 

Now, the new agency has made its choice — er, choices. ARPA-H will be housed in three main "hubs": Cambridge, Mass.; Dallas; and the D.C. suburbs. In addition, research "spokes" will be located in an initial 10 sites across the country, spanning from Alaska to Florida and touching most regions in between. 

The new structure, dubbed ARPANET-H, is an attempt to look ahead "10, 15 years from now to create an ecosystem that is going to be required to catch ARPA-H technologies," the agency's director, Renee Wegrzyn, told reporters. Read more from STAT's Sarah Owermohle and me.



Closer Look

GettyImages-1661265589PATRICK T. FALLON/AFP VIA GETTY IMAGES

An FDA advisory panel's recent conclusion that Sudafed and other over-the-counter decongestants don't work may have come as a surprise to anyone who suffers from the occasional head cold. But to many in the drug industry, the writing had been on the wall for years. In the words of PillPack co-founder T.J. Parker: "Didn't everyone know this?" 

The controversy has spotlighted a long-running dilemma with the country's drug approval system, STAT's Matt Herper argues in a new story: Once drugs are approved, they're generally approved forever, unless a specific and pressing issue forces the FDA to reevaluate decades-old decisions. 

Another key issue, Matt writes, is that there simply isn't the will or the funding to conduct post-approval clinical trials that could help avoid Sudafed-type drugs from remaining on the market even when it's clear there's no data to support their use. But major changes might require a full overhaul of the drug approval system and potentially an act of Congress. As Matt writes: Don't hold your breath. Read more.


MENTAL HEALTH

Higher suicide risks among health care workers 

It's no secret that health care jobs are hard on mental health. But as well documented as the physician mental health crisis is, no study has ever quantified the relative risk of suicide death across the entire spectrum of health workers — until now. 

A new study of nearly 2 million employed people within and outside of the health industry demonstrates that those in health care fields die by suicide more than 50% more often than those in other professions. The results were especially pronounced among women — suggesting, especially in a female-majority profession, that the psychological burden of health care delivery falls more heavily on women than men.

The results also highlight the burden of non-physician roles, the paper's lead author said, especially given that roles like health technicians, nurses, and support workers are often lower-paying, more repetitive, and provide fewer opportunities for career advancement. Read more from STAT's Annalisa Merelli.


health

Remembering the designer behind ubiquitous U.S. nutrition labels

There may be no graphic designer whose work you've interacted with more than Burkey Belser, best known for creating the uber-familiar black-and-white nutrition labels found on cereal boxes, candy bars, and just about any other packaged food item. 

Belser, who died this week at 76, has no doubt left his mark on U.S. food packaging. His passing may turn out to coincide with the beginning of a new era in U.S. food packaging — one in which companies marketing particularly unhealthy products could be forced to include warnings far starker than a back-of-the box label that lists grams of added sugar or overall carbohydrates. 

Those aggressive labels, which Mexico's government attempted to mandate four years ago, could soon be headed stateside, as STAT's Nicholas Florko recently reported. And the multinational companies like Unilever and Coca-Cola that have challenged the new Mexican law seem poised to do so in the U.S. — if the government ever tries to enact similar regulations. Read more here.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • Women face host of disadvantages in cancer prevention and care, report finds, STAT

  • US surgeons are killing themselves at an alarming rate. One decided to speak out, The Guardian

  • Just how much money do drugmakers gain from patent extensions? STAT

  • We carry DNA from extinct cousins like Neanderthals. Science is now revealing their genetic legacy, Associated Press

  • Bubble bursts: 2021 health tech IPO startups lose value, burn cash, STAT


Thanks for reading! More tomorrow — Lev


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments